ImmunoPrecise Antibodies Ltd. Asset Resilience Ratio
ImmunoPrecise Antibodies Ltd. asset resilience ratio. ImmunoPrecise Antibodies Ltd. (HYFT) has an Asset Resilience Ratio of 67.58% as of July 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ImmunoPrecise Antibodies Ltd. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ImmunoPrecise Antibodies Ltd. (1997–2020)
Asset resilience ratio of ImmunoPrecise Antibodies Ltd. from 1997 to 2020. This chart shows how ImmunoPrecise Antibodies Ltd.'s Asset Resilience Ratio has changed over time. Read HYFT liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ImmunoPrecise Antibodies Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ImmunoPrecise Antibodies Ltd. balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $27.54 Million | 67.58% |
| Total Liquid Assets | $27.54 Million | 67.58% |
Asset Resilience Insights
- Very High Liquidity: ImmunoPrecise Antibodies Ltd. maintains exceptional liquid asset reserves at 67.58% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ImmunoPrecise Antibodies Ltd. Industry Peers by Asset Resilience Ratio
Compare ImmunoPrecise Antibodies Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
ImmunoPrecise Antibodies Ltd. Asset Resilience Ratio by Year (1997–2020)
ImmunoPrecise Antibodies Ltd. asset resilience ratio by year from 1997 to 2020. The table below shows the annual Asset Resilience Ratio data for ImmunoPrecise Antibodies Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-04-30 | 0.00% | $104.00 | $27.26 Million | -15.51pp |
| 2016-04-30 | 15.51% | $214.14K | $1.38 Million | +15.22pp |
| 2010-04-30 | 0.30% | $16.20K | $5.47 Million | -0.17pp |
| 2009-04-30 | 0.47% | $32.50K | $6.93 Million | -4.44pp |
| 2008-04-30 | 4.91% | $253.25K | $5.16 Million | +3.85pp |
| 2007-04-30 | 1.06% | $58.75K | $5.56 Million | +0.83pp |
| 2006-04-30 | 0.22% | $9.00K | $4.05 Million | -0.59pp |
| 2001-04-30 | 0.81% | $9.40K | $1.16 Million | +0.24pp |
| 1999-04-30 | 0.57% | $9.40K | $1.66 Million | -6.17pp |
| 1998-04-30 | 6.73% | $197.32K | $2.93 Million | -50.56pp |
| 1997-04-30 | 57.30% | $2.22 Million | $3.88 Million | -- |
About ImmunoPrecise Antibodies Ltd.
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock ther… Read more